# US 2025/0367223 A1 · Methods for treating anxiety disorders, headache disorders, and eating disorders with psilocybin

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0367223 A1
- Document ID: US20250367223A1
- Status: Published application
- Kind: A1
- Application number: 19/296,581
- Filed: 2025-08-11
- Published: 2025-12-04
- Earliest claimed: 2019-04-17
- Assignees: Compass Pathfinder Limited
- Applicants: Compass Pathfinder Limited
- Inventors: Derek John LONDESBROUGH; Christopher BROWN; Julian Scott NORTHEN; Gillian MOORE; Hemant Kashinath PATIL; David E. NICHOLS; Hans Åke ERIKSSON; George GOLDSMITH; Ekaterina MALIEVSKAIA; Manon Cecile Elisabeth VERAART; Lars Christian WILDE
- Web page: https://patentgrep.com/patent/US20250367223A1

## CPC

- A61K 31/675: having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/20: Pills, tablets, {discs, rods (A61K9/0004, A61K9/0007, A61K9/0056, A61K9/0065 take precedence; for reconstitution of a drink A61K9/0095)}
- A61K 9/48: Preparations in capsules, e.g. of gelatin, of chocolate {(A61K9/0004 takes precedence; bite capsules A61K9/0056)}
- A61K 31/4045: Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
- A61K 31/661: Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion {or mevinphos}
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 25/06: Antimigraine agents
- A61P 25/08: Antiepileptics; Anticonvulsants
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/20: Hypnotics; Sedatives
- A61P 25/22: Anxiolytics
- A61P 25/24: Antidepressants
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 25/30: for treating abuse or dependence
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C07F 9/5728: {condensed with carbocyclic rings or carbocyclic ring systems}
- C07B 2200/13: Crystalline forms, e.g. polymorphs
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

The disclosure provides methods for treating a subject in need thereof comprising administering to the subject a therapeutically-effective dose of psilocybin. The methods described herein may be used to treat a variety of diseases, disorders, and conditions. For example, the methods may be used to treat anxiety disorders, eating disorders, and headache disorders.

## Claims

### Claim 1

A method of treating a bipolar disorder in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of crystalline psilocybin comprising Polymorph A characterized by XRPD peaks at 11.5±0.1, 12.0±0.1, 14.5±0.1, 17.5±0.1, and 19.7±0.1 °2θ, wherein the crystalline psilocybin has a chemical purity of greater than 97% as determined by HPLC analysis.

### Claim 2 (depends on 1)

The method of claim 1, wherein the subject has bipolar disorder I.

### Claim 3 (depends on 1)

The method of claim 1, wherein the subject has bipolar disorder II.

### Claim 4 (depends on 1)

The method of claim 1, wherein the crystalline psilocybin has no single impurity of greater than 1% as determined by HPLC analysis.

### Claim 5 (depends on 1)

The method of claim 1, wherein the crystalline psilocybin is administered in an oral dosage form.

### Claim 6 (depends on 5)

The method of claim 5, wherein the oral dosage form is a capsule.

### Claim 7 (depends on 5)

The method of claim 5, wherein the oral dosage form is a tablet.

### Claim 8 (depends on 1)

The method of claim 1, wherein about 1 mg to about 40 mg of crystalline psilocybin is administered.

### Claim 9 (depends on 1)

The method of claim 1, wherein about 1 mg of crystalline psilocybin is administered.

### Claim 10 (depends on 1)

The method of claim 1, wherein about 10 mg of crystalline psilocybin is administered.

### Claim 11 (depends on 1)

The method of claim 1, wherein about 25 mg of crystalline psilocybin is administered.

### Claim 12 (depends on 1)

The method of claim 1, wherein the subject participates in at least one psychological support session before administration of the crystalline psilocybin.

### Claim 13 (depends on 1)

The method of claim 1, wherein the subject participates in at least one psychological support session after administration of the crystalline psilocybin.

### Claim 14 (depends on 1)

The method of claim 1, wherein about 10 mg to about 30 mg of crystalline psilocybin is administered.

### Claim 15 (depends on 1)

The method of claim 1, wherein about 5 mg of crystalline psilocybin is administered.

### Claim 16 (depends on 1)

The method of claim 1, wherein the crystalline psilocybin of polymorph A is further characterized by at least one peak selected from the group consisting of 20.4±0.1, 22.2±0.1, 24.3±0.1, and 25.7±0.1 °2θ.
